Therapeutic approaches and novel antifibrotic agents in renal fibrosis: A comprehensive review

Abstract Renal fibrosis (RF) is one of the underlying pathological conditions leading to progressive loss of renal function and end‐stage renal disease (ESRD). Over the years, various therapeutic approaches have been explored to combat RF and prevent ESRD. Despite significant advances in understanding the underlying molecular mechanism(s), effective therapeutic interventions for RF are limited. Current therapeutic strategies primarily target these underlying mechanisms to halt or reverse fibrotic progression. Inhibition of transforming growth factor‐β (TGF‐β) signaling, a pivotal mediator of RF has emerged as a central strategy to manage RF. Small molecules, peptides, and monoclonal antibodies that target TGF‐β receptors or downstream effectors have demonstrated potential in preclinical models. Modulating the renin–angiotensin system and targeting the endothelin system also provide established approaches for controlling fibrosis‐related hemodynamic changes. Complementary to pharmacological strategies, lifestyle modifications, and dietary interventions contribute to holistic management. This comprehensive review aims to summarize the underlying mechanisms of RF and provide an overview of the therapeutic strategies and novel antifibrotic agents that hold promise in its treatment.